CellType Inc.

Based in the US, CellType Inc. operates as a biotechnology firm specializing in advanced simulations of drug responses by leveraging extensive human cell profile datasets to enhance drug efficacy and safety predictions. Founded in 2025, CellType Inc. is located in New York, US, and specializes in simulating drug responses within human biology.

The company has undergone a singular pivot in strategy since its inception. The firm has secured one deal as of March 18, 2026, when it raised seed funding from investors including Pioneer Fund and Y Combinator. The founder's background information is not provided. CellType specializes in advanced simulations of drug response within human biology, utilizing foundation models trained on extensive datasets of human cell profiles to understand and predict drug efficacy, toxicity, and patient variability.

Their flagship product, C2S-Scale, is a 27 billion-parameter model that processes over one billion tokens of transcriptomic data, enabling accurate predictions of human-specific toxicity and organ risk prior to Investigational New Drug (IND) applications. The company offers a range of tools for target selection, clinical trial design, and biomarker discovery, allowing clients to prioritize their testing processes effectively. Their services are tailored for pharmaceutical companies, biotech firms, and research institutions, with a focus on markets in North America, Europe, and Asia. By integrating multimodal biological data, CellType's offerings allow users to extract insights that traditional single-modality methods might overlook.

CellType generates revenue through partnerships and subscriptions with pharmaceutical and biotechnology companies seeking to enhance their drug development processes. Clients engage CellType to analyze their drug targets using the company's predictive models, receiving insights that inform their R&D strategies. The transaction structure typically entails service agreements or subscription-based models that provide ongoing access to CellType's technology and expertise. Specific pricing details for these services are proprietary; however, the company’s primary offerings, including C2S-Scale and related predictive insights, form the core of its business transactions.

By catering to the needs of its clientele, CellType is positioned to drive significant value in the drug discovery landscape. In March 2026, CellType Inc. raised an undisclosed amount of funding, which will support the development of new products aimed at enhancing their predictive modeling capabilities. The company plans to expand into additional markets in Europe and Asia by the end of 2027, targeting pharmaceutical companies engaged in drug development and clinical trials.

The funding will also facilitate the launch of enhancements to their flagship product, C2S-Scale, aimed at improving user experience and prediction accuracy.